Bayer Healthcare has looked to Otsuka Pharmaceuticals to replace its departing president Andreas Fibig.
Dieter Weinand, who is currently president global commercialisation and portfolio management at Otsuka’s US subsidiary, will step into his new role at Bayer Healthcare on August 1.
The announcement comes just one week after Weinand’s predecessor Fibig announced his intention to leave Bayer Healthcare to join International Flavors & Fragrances as CEO.
Bayer Healthcare’s parent group Bayer also announced this week that group CEO Marijn Dekkers will step down from his role at the end of 2016.
In addition to his time at Otsuka, Weinand boasts an impressive CV, serving across multiple regions and therapy areas for Pfizer and Bristole-Myers Squibb.
This includes roles as Pfizer’s president for Asia-Pacific and as president for BMS’ operations in Latin America and Canada.